High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain.
CONCLUSIONS: This multicenter study demonstrates high efficacy and an acceptable safety profile with regard to TBT in F2-patients in clinical practice.
PMID: 26019034 [PubMed - as supplied by publisher] (Source: Annals of Hepatology)
Source: Annals of Hepatology - May 30, 2015 Category: Gastroenterology Tags: Ann Hepatol Source Type: research
A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-α and ribavirin in patients infected with genotype 1 Hepatitis C virus
Journal of Medical Economics, Ahead of Print. (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - May 27, 2015 Category: Health Management Tags: article Source Type: research
TRIPLE THERAPY IN CHRONIC HEPATITIS C: initial series in a public health program in the South of Brazil
Conclusions In conclusion, despite the small number of patients treated with triple therapy evaluated in the current study, it possibly reflects the population under this therapy in real-life. Contexto A hepatite crônica pelo vírus C tem grande impacto na saúde mundial. A terapia atual do genótipo 1 inclui os inibidores de protease (IP) boceprevir e telaprevir, associados à terapia padrão - alfapeginterferona + ribavirina (PR). No Brasil ainda não há estudos publicados sobre os resultados dessa nova terapia, sendo de interesse uma avaliação do que foi realizado até o momento. Objetivos Avaliar a resposta virol...
Source: Arquivos de Gastroenterologia - May 23, 2015 Category: Gastroenterology Source Type: research
Does elevation of serum creatinine in patients with chronic hepatitis C under therapy of telaprevir mean renal impairment?
ConclusionElevation of SCr levels with TVR therapy may not suggest renal impairment. (Source: Nephrology)
Source: Nephrology - May 22, 2015 Category: Urology & Nephrology Authors: Katsuomi Matsui, Atsuko Kamijo‐Ikemori, Takeshi Sugaya, Hiroki Ikeda, Chiaki Okuse, Yugo Shibagaki, Takashi Yasuda, Kenjiro Kimura Tags: Original Article Source Type: research
Telaprevir‐induced moderate cutaneous eruptions associated with hhv‐6 reactivation
This article is protected by copyright. All rights reserved (Source: Journal of Medical Virology)
Source: Journal of Medical Virology - May 15, 2015 Category: Virology Authors: Francesco Broccolo, Giulia Ciccarese, Arianna Fay Agnoletti, Linda Bruzzone, Paola Calamaro, Roberta Zappacosta, Massimo Oggioni, Aurora Parodi, Francesco Drago Tags: Letter to the Editor Source Type: research
Vitamin D‐related gene polymorphisms do not influence the outcome and serum vitamin D level in pegylated interferon/ribavirin therapy combined with protease inhibitor for patients with genotype 1b chronic hepatitis C
In conclusions, the IL28B polymorphism and serum 25(OH) D3 level contributed significantly and independently to SVR in PR combined with PI for genotype 1b‐infected chronic hepatitis C patients. However, none of vitamin D‐related gene polymorphisms had an impact on the treatment outcome and serum 25(OH) D3 level. (Source: Journal of Medical Virology)
Source: Journal of Medical Virology - May 11, 2015 Category: Virology Authors: Taeang Arai, Masanori Atsukawa, Akihito Tsubota, Chisa Kondo, Noritomo Shimada, Hiroshi Abe, Norio Itokawa, Ai Nakagawa, Tomomi Okubo, Yoshio Aizawa, Katsuhiko Iwakiri Tags: Research Article Source Type: research
Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus-Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin
In conclusion, CXCL10 identified very rapid virological response in patients treated with a direct-acting antiviral.
Clinical Trials Registration. NCT00892697. (Source: The Journal of Infectious Diseases)
Source: The Journal of Infectious Diseases - May 9, 2015 Category: Infectious Diseases Authors: Zeremski, M., Dimova, R. B., Benjamin, S., Penney, M. S., Botfield, M. C., Talal, A. H. Tags: VIRUSES Source Type: research
Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C.
Abstract
Telaprevir and Boceprevir are the first direct acting antivirals approved for chronic hepatitis C in combination with peg-interferon alfa and ribavirin. Pancytopenia due to myelotoxicity caused by these drugs may occur, but severe hematological abnormalities or aplastic anemia (AA) have not been described. We collected all cases of severe pancytopenia observed during triple therapy with telaprevir in four Spanish centers since approval of the drug in 2011. Among 142 cirrhotic patients receiving treatment, 7 cases of severe pancytopenia (5%) were identified and three were consistent with the diagno...
Source: World Journal of Gastroenterology : WJG - May 7, 2015 Category: Gastroenterology Authors: Lens S, Calleja JL, Campillo A, Carrión JA, Broquetas T, Perello C, de la Revilla J, Mariño Z, Londoño MC, Sánchez-Tapias JM, Urbano-Ispizua Á, Forns X Tags: World J Gastroenterol Source Type: research
Telaprevir decreases estimated glomerular filtration rate in HIV-hepatitis C virus coinfected patients
We investigated kidney function outcome in 24 chronic hepatitis C genotype 1 patients coinfected with HIV receiving telaprevir in a single tertiary care hospital in Spain. A statistically significant median (interquartile range) decrease in estimated glomerular filtration rate (eGFR, ml/min/1.73 m2) relative to baseline [93.6 (73.0–109.0)] was seen at weeks 4 [86.5 (34.0–112.0), P = 0.014], 8 [90.0 (49.0–111.0), P = 0.026] and 12 [89.5 (54.0–113.0), P = 0.017]. These changes reversed after telaprevir discontinuation. Patients presenting an eGFR decrease had a higher risk of haematological toxicity. (Source: AIDS)
Source: AIDS - May 1, 2015 Category: Infectious Diseases Tags: Research Letter Source Type: research
Relative Efficacy of Simeprevir (Smv) Versus Telaprevir (Tpv) In The Treatment of NaÏVe Genotype 1 Chronic Hepatitis C Patients, Based on Indirect Comparison Using Patient-Level Clinical Trial Data
To indirectly estimate the relative treatment effect of 12 weeks of treatment with SMV versus TPV in combination with response-guided background therapy of 24/48 weeks of Peginterferon/ribavirine (PR) in previously untreated patients with genotype 1 chronic hepatitis C virus infection, using patient-level data from the pivotal phase III-trials. (Source: Value in Health)
Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: J Diels, P Thilakarathne, S Van Sanden, U Sbarigia, A Mehnert Source Type: research
Combining Disease Transmission and Numbers Treated in Conventional Cost-Effectiveness Analyses of Hepatitis C Treatment In the UK
This study evaluated the health economic impact of two treatment regimens, daclatasvir+sofosbuvir (DCV+SOF) and telaprevir+pegylated interferon-alfa+ribavirin (TVR+PR), in a cohort of people with high transmission risk, when accounting for future infections avoided. (Source: Value in Health)
Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: P. McEwan, H. Bennett Wilton, S. Webster, A. Kalsekar, Y. Yuan, M. Brenner Source Type: research
Past trends and current challenges in the hepatitis c reimbursement landscape: is history repeating itself?
In 2011, the introduction of boceprevir and telaprevir was hailed as a breakthrough in the hepatitis C (HCV) treatment paradigm, but these treatments were not widely adopted due to cost and safety concerns. 4 years on, the introduction of newer, more effective therapies (e.g. simeprevir and sofosbuvir) has re-revolutionized the HCV space. However, cost concerns continue to limit the number of patients being treated with new medicines. To inform future submissions, HCV reimbursement decisions across 5 HTA agencies were assessed and the underlying rationale examined. (Source: Value in Health)
Source: Value in Health - May 1, 2015 Category: Global & Universal Authors: E.A. Griffiths, L.A. Noble Source Type: research
Development of hypocalcemia with telaprevir-based triple treatment in a case of genotype 1 chronic hepatitis C.
PMID: 26006210 [PubMed - in process] (Source: The Turkish Journal of Gastroenterology)
Source: The Turkish Journal of Gastroenterology - May 1, 2015 Category: Gastroenterology Authors: Şenateş E, Çolak Y, Yeşil A, Tuncer İ Tags: Turk J Gastroenterol Source Type: research
Development of antiviral drugs for the treatment of hepatitis C at an accelerating pace
Summary
Anno 2015, the race for developing the ideal therapy, or what is now called “cure,” for hepatitis C virus infection has continued unabatedly. The targets (NS3/4A protease, NS5A protein, and NS5B polymerase) have remained the same, and the number of compounds [direct‐acting antivirals (DAAs)] interacting with these targets has continued to increase. Whereas pan‐genotypic activity has remained a mandatory requirement, the problem of virus drug resistance has become less crucial. The need for combining DAAs acting at different sites has remained compelling, with the drugs used for combinations emanating from t...
Source: Reviews in Medical Virology - May 1, 2015 Category: Virology Authors: Erik De Clercq Tags: Review Source Type: research
Impact of all oral anti-hepatitis C virus therapy: A meta-analysis.
CONCLUSION: Second generation and emerging DAAs are promising agents in HCV treatment, with a very high level of safety and efficacy. An important drawback is their high cost. However, the present meta-analysis shows that the cost per SVR for non responders (but not for naive patients) was lower compared to P + R. This finding together with the superior safety profile and better compliance makes these drugs highly attractive. It is possible that further reduction in treatment duration may make them even more cost effective.
PMID: 25914781 [PubMed] (Source: World Journal of Hepatology)
Source: World Journal of Hepatology - April 30, 2015 Category: Gastroenterology Tags: World J Hepatol Source Type: research
